Monopar Therapeutics Inc ((MNPR)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Monopar Therapeutics Inc. is conducting a Phase 1a clinical study titled Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers. The study aims to assess the safety of MNPR-101-PCTA-177Lu, a drug designed to treat various solid tumor cancers, including bladder, lung, and breast cancer. This research is significant as it explores new treatment avenues for these challenging conditions.
The intervention being tested is MNPR-101-PCTA-177Lu, an experimental drug administered intravenously. It is intended to target and treat solid tumors by delivering radioactivity directly to cancer cells, potentially improving treatment outcomes.
The study follows a non-randomized, sequential intervention model, with no masking involved. Participants are grouped in cohorts of two, and the dosing strategy is adjusted based on safety outcomes using the TITE-BOIN method. The primary purpose of the study is treatment-focused.
The study began on September 18, 2024, with a primary completion date not yet reached. The latest update was submitted on May 19, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
Market implications of this study update could be significant for Monopar Therapeutics’ stock performance. Positive safety outcomes may boost investor confidence and interest in the company, especially as it positions itself within a competitive oncology market. Investors should watch for further updates as the study progresses.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.